OTX-2002
omega Theraputics
$omga omega therapeutics presents new preclinical data supporting the first epigenomic controller, otx-2002, as a potential therapeutic approach in hepatocellular carcinoma at the esmo 2022 world congress on gastrointestinal cancer 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities